

**CHARACTERIZATION OF 1-ACBP, B-ACBP AND PBR IN
OESOPHAGEAL CANCER.**



MICHELLE LYNN McCABE

**A dissertation submitted to the Faculty of Science, University of the
Witwatersrand, Johannesburg, in fulfilment of the requirements for
the degree of Master of Science**

Johannesburg, 2005

DECLARATION

I (Michelle McCabe) declare that this thesis is my own work. It is being submitted for the Degree of Master of Science in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination in any other University.

(Signature of candidate)

_____ day of _____ 200__

PUBLICATIONS:

- McCabe M.L and Dlamini Z. (2005) Mini review: The molecular mechanisms of oesophageal cancer. *International journal of immunology*, **5(7-8)**: 113-130.
- 1-ACBP, B-ACBP and PBR in oesophageal cancer (in preparation).
- Poster presentation at South African Society of Biochemistry and Molecular Biology- Title: Characterization of 1-ACBP, B-ACBP and PBR in Oesophageal cancer. SASBMB XIXth Conference, 16-20 January 2005, Stellenbosch University Pg228.
- Abstract accepted for poster presentation at the American Association of Cancer Research. Title: Characterization of 1-ACBP, B-ACBP and PBR in Oesophageal cancer. (AACR) 96th Annual meeting, 16-20 April 2005, Anaheim California.

DEDICATION

I dedicate this work to my family, especially my mother and father for their love, patience and support, my three brothers for their love and support and hope that it will inspire them, and to my late sister who passed away from brain cancer inspiring me to be who I am today. And to everyone who supported me during my studies.

ACKNOWLEDGEMENTS

I would like to thank my supervisor, Dr Zodwa Dlamini, and co-supervisor, Prof Sarala Naicker, for their support and guidance during my studies.

I would also like to thank Zukile Mbita for his constant help.

I would like to thank Prof Jasper Rees for his expertise and help with my project.

I would like thank my labmates at the Molecular and Cellular Pathology Research laboratory for their assistance and support.

I would also like to thank Prof Stewart Goetsch for the tissue sections as well as for assisting me with histopathology.

Thanks to Rodney Hull from the Flylab for assisting me with microscope work.

I would like to thank the NRF, MRC and URC for funding.

Contents Page

Chapter 1: Molecular mechanisms of oesophageal cancer

1.1 Prevalence of oesophageal cancer

1.2 Aetiology

1.3 Pathology of oesophageal cancer

1.3.1 Normal oesophageal histology

1.3.2 Squamous carcinoma

1.3.3 Adenocarcinoma

1.4 Molecular genetics of oesophageal cancer

1.4.1 Apoptotic genetic regulation of oesophageal cancer

1.4.1.1 Intrinsic mitochondrial pathway

1.4.1.2 Extrinsic death receptor pathway

1.4.2 HPV and squamous cell transformation

1.4.3 Telomerase activity

1.4.4 Oncogenes

1.4.4.1 Cyclin D1

1.4.4.2 Frat 1

1.4.5 Tumour suppressor genes

1.4.5.1 p53

1.4.5.2 Rb

1.4.5.3 DLC1

1.4.5.4 P16INK49 and P15INK4b

1.4.5.5 APC and MCC

1.4.5.6 WWOX

1.4.6 Other apoptotic genes

1.4.6.1 Bcl-2

1.4.6.2 FAS

1.4.6.3 Survivin

1.4.6.4 DcR3/M68

1.4.6.5 E2F-1

1.4.6.6 Metallothionein

1.4.6.7 Matrix metalloproteinase-7

1.4.6.8 PCNA

1.4.7 Other genes believed to play a role in the development of oesophageal cancer

1.4.7.1 FEZ 1

1.4.7.2 FzE 3

1.4.7.3 ODC

1.4.7.4 Annexin 1

1.4.7.5 Cathepsin B

1.4.7.6 GASC 1

1.4.7.7 ECRG 4

1.4.8 Angiogenesis

1.4.9 Invasion and metastasis

1.5 Potential therapeutic strategies in oesophageal cancer

1.6 Objectives of the research

1.6.1 Aycl-coenzymeA binding protein (ACBP)

1.6.2 Peripheral-type benzodiazepine receptor (PBR)

1.6.3 PBR and ACBP interactions

1.6.4 PBR and ACBP in diseases

1.6.5 PBR and ACBP in Blood Cells

1.6.6 PBR and ACBP in immunomodulation

1.7 Summary

Chapter 2: Materials and Methods

2.1 *In Situ* Hybridization

2.1.1 Probe Synthesis

2.1.1.1 Primer design and synthesis

2.1.1.2 Reverse transcription polymerase chain reaction (RT-PCR)

2.1.1.3 Polymerase Reaction (PCR)

2.1.1.4 Agarose gel electrophoresis

2.1.1.5 Cloning of PCR products into pGEM-T-Easy vectors

2.1.1.6 Transformation

2.1.1.7 Screening for positive colonies using colony PCR

2.1.1.8 Plasmid DNA extraction

2.1.1.9 Restriction Digestion

2.1.1.10 Sequencing

2.1.1.11 Clone Linearization

2.1.1.12 Purification of linearized clones from an agarose gel

2.1.1.13 Dig labeling of probes

2.1.1.14 Probe concentration estimation

2.1.2 Localization of 1-ACBP, B-ACBP and PBR mRNA by in situ hybridization

2.1.2.1 Preceding ISH

2.1.2.2 Pre-hybridization treatment of sections

- 2.1.2.3** Hybridization of sections
- 2.1.2.4** Post-Hybridization washes and detection of bound probes
- 2.1.2.5** Colorimetric method protocol for in situ hybridization
- 2.1.2.6** Fluorescent method protocol for in situ hybridization

2.2 Protein expression

- 2.2.1** pGEX expression vectors
- 2.2.2** Preparation of E.coli competent cells for transformation
- 2.2.3** Transformation of E.coli cells
- 2.2.4** Large-scale preparation of plasmid DNA
- 2.2.5** PEG precipitation
- 2.2.6** Small-scale preparation of plasmid DNA
- 2.2.7** Restriction digests of pGEX-6P-2
- 2.2.8** PCR amplifications for ORFs of 1-ACBP, B-ACBP and PBR
- 2.2.9** Cloning into pGEM for sequencing
- 2.2.10** Restriction Digestion of pGEM vectors plus insert
- 2.2.11** Cloning into pGEX-6P-2 vector
- 2.2.12** Transformation of E.coli with recombinant DNA
- 2.2.13** Colony PCR
- 2.2.14** Sequencing of pGEX vectors
- 2.2.15** Protein expression
- 2.2.16** SDS-page gel electrophoresis

2.3 Solutions and Reagents

Chapter 3: Results

3.1 Normal Histology and Tumor Histopathology of the Oesophagus

3.1.1 Normal oesophagus

3.1.2 Cancer of the oesophagus

3.2 Introduction on genes

3.2.1 In Situ Hybridization

3.2.1.1 Cloning of l-ACBP, b-ACBP and PBR into pGEM[®]-T-Easy

3.2.1.1.1. PCR Primer design for l-ACBP, b-ACBP and PBR probe synthesis

3.2.1.1.2. RT-PCR amplification of l-ACBP, b-ACBP and PBR

3.2.1.1.3 Cloning of l-ACBP, b-ACBP and PBR into pGEM[®]-T-Easy

3.2.1.2 Generation of l-ACBP, b-ACBP and PBR Dig labeled probes for *In situ* hybridization

3.2.1.2.1 Restriction digestion of l-ACBP, b-ACBP and PBR

3.2.1.2.2 Sequencing analysis of l-ACBP, b-ACBP and PBR

3.2.1.2.3 Generation of l-ACBP, b-ACBP and PBR Dig labelled probes

3.2.1.3 Localization of l-ACBP, b-ACBP and PBR in diseased and normal tissue

3.2.1.4 Summary

3.3. Protein expression and purification of l-ACBP, B-ACBP and PBR

3.3.1 Introduction

3.3.1.1. Cloning l-ACBP, B-ACBP and PBR ORF into pGEX-6P-2

3.3.1.1.1 RT-PCR amplification of l-ACBP, B-ACBP and PBR ORF cDNA

3.3.1.1.3 Sequencing

3.3.1.1.4 Sub-Cloning l-ACBP, b-ACBP and PBR sequences into pGEX-6P-2

3.3.1.1.5 Sequencing results

3.3.1.1.7 Screening for the expression and solubility of B-ACBP

3.3.2 Summary

3.4 Quantitative Gene analysis of 1-ACBP, B-ACBP and PBR in oesophageal cancer

3.4.1 Absolute Quantification of 1-ACBP in oesophageal cDNA

3.4.2 Absolute Quantification of B-ACBP in oesophageal cancer cDNA

3.4.3 Absolute Quantification of PBR in oesophageal cancer cDNA

3.4.4 Absolute Quantification and correlation of 1-ACBP, B-ACBP and PBR in

oesophageal cancer

3.4.5 Summary

Chapter 4: Discussion

4.1 PBR, 1-ACBP and B-ACBP localization studies in oesophageal cancer

4.1.1 In Situ hybridization

4.1.2 Protein expression of 1-ACBP, B-ACBP and PBR

4.1.3 Quantitative Gene analysis of 1-ACBP, B-ACBP and PBR in oesophageal cancer

Chapter 5: Conclusion

Tables:

Table 1: RT-PCR mixture

Table 2: RT-PCR Thermocycle Conditions

Table 3: PCR Reaction mixture

Table 4: PCR Thermocycle conditions

Table 5: Ligation of PCR products into pGEM-T-Easy

Table 6: Restriction digestion by EcoRI and PstI

Table 7: Restriction digests with PstI and ApaI

Table 8 Cocktail for Dig Labeling

Table 9 Dilutions to estimate concentration of probe

Table 10: Restriction digestion

Table 11: PCR reagents

Table 12: Thermocycle conditions: for each set of primer for each gene

Table 13: Annealing temperatures

Table 14: Cloning into pGEX-6P-2 vector

Table 15: Different IPTG concentrations for protein induction

Table 16: Separating gel reagents

Table 17: Stacking gel reagents

Table 18: LightCycler Master Mix reaction mixture:

Table 19: Composition of solutions

Table 20: Primers for 1-ACBP, B-ACBP and PBR RT-PCR products

Table 21: 1-ACBP probe expression and localization

Table 22: B-ACBP probes expression and localization

Table 23: PBR probes expression and localization

Table 24: Primers for ORF and ORF plus restriction enzyme site amplification

Tables:

Table 1: RT-PCR mixture

Table 2: RT-PCR Thermocycle Conditions

Table 3: PCR Reaction mixture

Table 4: PCR Thermocycle conditions

Table 5: Ligation of PCR products into pGEM-T-Easy

Table 6: Restriction digestion by EcoRI and PstI

Table 7: Restriction digests with PstI and ApaI

Table 8 Cocktail for Dig Labeling

Table 9 Dilutions to estimate concentration of probe

Table 10: Restriction digestion

Table 11: PCR reagents

Table 12: Thermocycle conditions: for each set of primer for each gene

Table 13: Annealing temperatures

Table 14: Cloning into pGEX-6P-2 vector

Table 15: Different IPTG concentrations for protein induction

Table 16: Separating gel reagents

Table 17: Stacking gel reagents

Table 18: LightCycler Master Mix reaction mixture:

Table 19: Composition of solutions

Table 20: Primers for 1-ACBP, B-ACBP and PBR RT-PCR products

Table 21: 1-ACBP probe expression and localization

Table 22: B-ACBP probes expression and localization

Table 23: PBR probes expression and localization

Table 24: Primers for ORF and ORF plus restriction enzyme site amplification

Figures:

Figure 1: Explanatory diagram of the longitudinal section of the normal oesophagus

Figure 2: Simple schematic diagram of normal cell cycle progression leading to mitosis (M) or cell growth (if DNA is intact) or apoptosis (if DNA damage occurs).

Figure 3: Intrinsic apoptotic pathway triggered by p53

Figure 4: Fas apoptotic signaling pathway

Figure 5: Role of p53 in cell cycle: Mediator between cell growth and death

Figure 6: Oesophageal cancer and mutant p53

Figure 7: Wildtype vs mutant p53, and the affect it has on the cell cycle, G1/S phase

Figure 8: Abberant Bax and Bcl-xl expression in oesophageal cancer cells

Figure 9: Fas expression in oesophageal cancer

Figure 10: The three dimensional structure of bovine ACBP by NMR studies

Figure 11: Illustration of 2 cycles of 30 cycles of PCR reaction

Figure 12: Ligafast pGEM-T-Easy cloning system kit (Promega™)

Figure 13: pGEX cloning vector

Figure 14: H&E of a normal oesophageal tissue section

Figure 15: H&E of a high grade invasive squamous cell carcinoma

Figure 16: H&E of a high grade squamous cell carcinoma

Figure 17: H&E of a tumour in a high-grade squamous cell carcinoma

Figure 18: H&E of a high grade in-situ squamous cell carcinoma

Figure 19: H&E of a Keratin Pearl in a high grade in-situ squamous cell carcinoma

Figure 20: Signal cell in a high grade squamous cell carcinoma

Figure 21: Epithelium of a high-grade squamous cell carcinoma

Figure 22: Section from Gastroesophageal junction showing Barrett's oesophagus
With goblet cells

Figure 23: General structure of Dig nucleotides

Figure 24: Schematic representation of the NBT/BCIP reaction

Figure 25: RT-PCR products of 1-ACBP and B-ACBP PCR products

Figure 26: Agarose gel electrophoresis of restriction digestions

Figure 27: Agarose gel electrophoresis of restriction digests

Figure 28: PBR RT PCR and restriction digestion products

Figure 29: Sequencing results of the two 1-ACBP inserts

Figure 30: Sequencing results of the 2 B-ACBP inserts

Figure 31: Sequencing results of the PBR insert

Figure 32: Experimental controls for ISH, on the diseased oesophagus

Figure 33: Localization of 3'1-ACBP on diseased oesophageal tissue

Figure 34: 3'1-ACBP localization on diseased and normal lamina propria

Figure 35: 5'1-ACBP localization within the submucosa

Figure 36: 5'1-ACBP localization to diseased and normal arteries in submucosa

Figure 37: 5'1-ACBP in connective tissue and submucosa of diseased tissue.

Figure 38: 3'B-ACBP localization to diseased and normal oesophageal tissue

Figure 39: Localization within the muscularis externa of the diseased oesophagus

Figure 40: 3'B-ACBP localization in diseased and normal lamina propria

Figure 41: Comparative analysis of 5'B-ACBP in diseased and normal epithelium

Figure 42: 5'B-ACBP localization in diseased and normal lamina propria

Figure 43: Colorimetric in situ hybridization results of 5'B-ACBP

Figure 44: PBR localization within the Mucous acini glands in diseased and normal oesophageal tissue sections.

Figure 45: PBR localization within diseased and normal lamina propria

Figure 46: PBR localization in an invasive squamous carcinoma tissue section

Figure 47: Fluorescent in situ hybridization results of 5'1-ACBP

Figure 48: Localization of 1-ACBP in mucini glands in the submucosa

Figure 49: B-ACBP localization within fat cells of low and high-grade carcinoma

Figure 50: 3'B-ACBP FITC ISH results

Figure 51: PBR localization in the mucosa of normal and diseased oesophagus

Figure 52: FITC ISH results of the PBR probe

Figure 53: RT-PCR products of PBR and 1-ACBP ORF:

Figure 54: B-ACBP RT-PCR products

Figure 55: ORF sequence of B-ACBP in pGEX in the correct open reading frame

Figure 56: ORF sequence of PBR in pGEX in the correct open reading frame

Figure 56: PBR and B-ACBP protein lysates on an SDS page gel

Figure 57: Amplification curves in the quantification module of the LightCycler Software 3.5 (channel F1, arithmetic baseline adjustment).

Figure 58: 3'/ 5' and open reading frame expression correlation of the 1-ACBP gene

Figure 59: 3'/ 5' and open reading frame expression correlation of the B-ACBP gene

Figure 60: PBR probe cDNA sequence and the open reading frame expression

Correlation

Figure 61: Open reading frame gene expression of 1-ACBP, B-ACBP and PBR

Abbreviations:

5-FU	5-fluorouracil
ACBP	AcylcoenzymeA binding protein
AINs	Apoptosis inducing nucleosides
ANC	Adenine nucleotide carrier
Apaf-1	Apoptosis activating factor 1
APC	Adenomatous polyposis coli
BAAC	Barrets oesophagus associated adenocarcinoma
BCH	Basal cell hyperplasia; BE, Barret's Esophagus
Bcl-2	B-cell lymphoma mutant #2
Bcl-xl	B-cell lymphoma extra long
cAMP	Cyclic adenosine monophosphate
CDDP	Cisplatin
CDK	Cyclin dependent kinase
CNS	Central Nervous System
COX-2	Cyclooxygenase 2
CSNK	Casein kinase
CTSB	Cathepsin B;
DBI	Diazepam binding inhibitor (DBI)
DcR3	Decoy receptor member 3
DISC	Death inducing signalling complex

DLC1	Deleted in lung cancer 1
EMR	Endoscopic mucosal resection
FasL	Fas receptor ligand
GASC1	Gene amplified in squamous cell carcinoma 1
iNOS	Inducible nitric oxide synthase
Lef	Lymphoid enhancer binding factor
LOH	Loss of Heterozygosity
LOI	Loss of imprinting
MMP-7	Matrix metalloproteinase-7
MPTP	Mitochondrial Permeable Transition Pore
MT	Metallothionein; MTX, Methotrexate
ODC	Ornithine Decarboxylase
P450 _{scc}	Cytochrome P450 enzyme
p53	Protein with molecular weight ~53kD
p63	Protein with molecular weight ~63kD
p73	Protein with molecular weight ~73kD
PARP	Poly-ADP-ribose polymerase
PBR	Peripheral Benzodiazepine-type Receptor
PCNA	Proliferating cell nuclear antigen
PDT	Photodynamic therapy
pRb	Retinoblastoma protein

Rb	Restinoblastoma
Tcf	T cell specific transcription factor
TNF- β	Tumor necrosis factor- β
TSGs	Tumour Suppressor Genes
VDAC	Voltage-dependant anion channel
WWOX	WW domain containing oxireductase